Meeting
2018 Genitourinary Cancers Symposium
Outcomes of patients (pts) with metastatic clear-cell renal cell carcinoma (mCCRCC) treated with second-line (2L) vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) after first-line (1L) immune checkpoint inhibitors (ICI).
Authors
Amishi Yogesh Shah
UT MD Anderson Cancer Center, Houston, TX
Amishi Yogesh Shah , Emily Lemke , Jianjun Gao , Anuradha Chandramohan , Matthew T. Campbell , Amado J. Zurita , Lianchun Xiao , Jennifer Wang , Paul Gettys Corn , Eric Jonasch , Padmanee Sharma , Nizar M. Tannir
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 682)
DOI
10.1200/JCO.2018.36.6_suppl.682
Abstract #
682
Poster Bd #
K11
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Outcomes of patients with metastatic clear cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
First Author: Amishi Yogesh Shah
Poster
2020 ASCO Virtual Scientific Program
Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.
First Author: Shaan Dudani
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-world assessment of changing treatment patterns and sequence for patients with metastatic renal cell carcinoma (mRCC) in the first-line (1L) setting.
First Author: Neil J. Shah
Poster
2021 ASCO Annual Meeting
Outcomes of immunotherapy (ICI) alone vs tyrosine kinase inhibitors (TKI) alone versus ICI and TKI combined in renal cell carcinoma brain metastasis.
First Author: Patrick Joseph O'Shea